BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Last trade$58.23
Day change+$0.24 (+0.41%)
Day range$57.39 – $58.64
Volume945,076
Market cap$11.23B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$11.23B
Price / earnings
—
Price / book
1.8×
Price / sales
3.07×
EV / sales
4.01×
EV / EBITDA
38.39×
Profitability
Earnings per share
-$0.10
Return on assets
-0.17%
Return on equity
-0.31%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.67×
Current ratio
2.44×
Quick ratio
1.32×
Cash ratio
0.46×
Cash flow
Price / cash flow
16.6×
Price / free cash flow
20.13×
Free cash flow
$557.86M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BMRN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.02B
$989.71M
$766.21M
$874.57M
$776.13M
$825.41M
$745.15M
$747.31M
Cost of revenue
$205.42M
$202.8M
$195M
$275.71M
$140.09M
$150.09M
$151.56M
$136.14M
Gross profit
$819.23M
$786.91M
$571.21M
$598.86M
$636.05M
$675.32M
$593.59M
$611.17M
Selling, general and administrative
$333.64M
$395.55M
$258.29M
$446.21M
$268.42M
$232.28M
$206.12M
$266.61M
Research and development
$468.21M
$206.95M
$178.8M
$192.41M
$409.48M
$161.31M
$158.73M
$173.51M
Total operating expenses
$901.31M
$672.71M
$441.57M
$643.47M
$682.74M
$393.6M
$369.69M
$449.77M
Operating income
-$82.08M
$114.2M
$129.64M
-$44.61M
-$46.69M
$281.72M
$223.89M
$161.41M
Interest expense
-$55.63M
-$63.3M
-$14.96M
-$2.78M
-$2.58M
-$2.68M
-$2.86M
-$2.58M
Income before taxes
-$131.77M
$61.38M
$141.2M
-$27.15M
-$26.32M
$297.87M
$238.09M
$169.64M
Income taxes
-$8.94M
$16.62M
$35.68M
$19.42M
$4.42M
$57.34M
$52.4M
$44.7M
Net income
-$122.83M
$44.76M
$105.53M
-$46.57M
-$30.74M
$240.53M
$185.69M
$124.94M
Net income attributable to common shareholders
-$122.83M
$44.76M
$105.53M
-$46.57M
-$30.74M
$240.53M
$185.69M
$124.94M
EBITDA
$48.38M
$211.84M
$146.05M
-$24.17M
-$28.21M
$300.28M
$245.96M
$185.01M
Basic earnings per share
-$0.63
$0.23
$0.55
-$0.24
-$0.16
$1.25
$0.97
$0.66
Diluted earnings per share
-$0.63
$0.23
$0.54
-$0.23
-$0.16
$1.23
$0.95
$0.66
Recent news
Company coverage with links to the original publishers.
The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.
Neion Bio announced the appointment of John A. Maga, Ph.D., as Head of Biologics and CMC. Maga brings over 25 years of biopharmaceutical experience, including 15 years at BioMarin Pharmaceutical. He will lead biologics development and expand Neion's Raptor platform capabilities for producing complex therapeutic proteins using transgenic chickens.
BioMarin reported Q3 2026 revenue of $1.02 billion, slightly missing the $1.03 billion consensus estimate but delivering a significant EPS surprise of $0.23 versus the expected -$0.09. The company showed mixed product performance, with strong growth in VIMIZIM (+18% YoY) and BRINEURA (+10.4% YoY), offset by declines in NAGLAZYME (-11.5% YoY) and PALYNZIQ missing estimates. The stock holds a Zacks Rank #3 (Hold) rating.
BioMarin Pharmaceutical (BMRN) reported quarterly earnings of $0.23 per share, significantly beating the consensus estimate of a loss of $0.09 per share, representing a +355.56% earnings surprise. Revenue reached $1.02 billion, slightly missing estimates by 0.23%. The company has surpassed EPS estimates three times over the last four quarters. However, BMRN shares have underperformed the market, down 1.6% year-to-date versus the S&P 500's 10.7% gain. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revision trends.
BioMarin Pharmaceutical is expected to report Q3 2026 earnings of $1.35 per share (up 1025% YoY) with revenues of $1.03 billion (up 32.7% YoY). The company has a positive Earnings ESP of +9.40% with a Zacks Rank #3 (Hold), suggesting it is likely to beat consensus estimates. BioMarin has beaten EPS estimates in 3 of the last 4 quarters, most recently delivering a +25% surprise.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.